Omnicell Inc. (NASDAQ:OMCL) saw unusually-high trading volume on Friday . Approximately 310,696 shares were traded during mid-day trading, an increase of 71% from the previous session’s volume of 181,523 shares.The stock last traded at $37.78 and had previously closed at $37.44.

OMCL has been the topic of several research reports. Sidoti downgraded Omnicell from a “buy” rating to a “neutral” rating and set a $43.00 target price on the stock. in a research report on Thursday, September 8th. FBR & Co raised their target price on Omnicell from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Thursday, July 7th. Zacks Investment Research upgraded Omnicell from a “sell” rating to a “hold” rating in a research report on Wednesday, June 29th. Finally, Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $46.00 target price on shares of Omnicell in a research report on Tuesday, September 13th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $38.13.

The company’s 50 day moving average price is $37.77 and its 200-day moving average price is $32.72. The firm has a market cap of $1.37 billion, a P/E ratio of 96.32 and a beta of 0.69.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, July 28th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.32 by $0.06. The business earned $175.60 million during the quarter, compared to the consensus estimate of $170.89 million. Omnicell had a return on equity of 10.41% and a net margin of 2.36%. The company’s revenue for the quarter was up 55.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.28 EPS. Analysts expect that Omnicell Inc. will post $1.58 EPS for the current fiscal year.

In related news, Chairman Randall A. Lipps sold 37,425 shares of the company’s stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $37.37, for a total value of $1,398,572.25. Following the sale, the chairman now owns 192,325 shares in the company, valued at approximately $7,187,185.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Robin Gene Seim sold 5,302 shares of the company’s stock in a transaction that occurred on Wednesday, July 6th. The stock was sold at an average price of $34.75, for a total value of $184,244.50. Following the completion of the sale, the executive vice president now owns 55,420 shares in the company, valued at approximately $1,925,845. The disclosure for this sale can be found here. 3.75% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the company. Zebra Capital Management LLC boosted its stake in Omnicell by 24.6% in the first quarter. Zebra Capital Management LLC now owns 17,102 shares of the company’s stock worth $477,000 after buying an additional 3,379 shares in the last quarter. Menta Capital LLC purchased a new stake in Omnicell during the first quarter worth $332,000. BlackRock Group LTD boosted its stake in Omnicell by 33.9% in the first quarter. BlackRock Group LTD now owns 56,209 shares of the company’s stock worth $1,567,000 after buying an additional 14,243 shares in the last quarter. Teachers Advisors Inc. boosted its stake in Omnicell by 9.2% in the first quarter. Teachers Advisors Inc. now owns 375,920 shares of the company’s stock worth $10,477,000 after buying an additional 31,762 shares in the last quarter. Finally, Icon Advisers Inc. Co. purchased a new stake in Omnicell during the first quarter worth $825,000. Institutional investors and hedge funds own 95.26% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.

5 Day Chart for NASDAQ:OMCL

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.